Clinical trial · Observational
Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The recurrent pancreatic cancer (Rec-PC) after radical surgery is sometimes eligible to clinical trial of chemotherapy for unresectable pancreatic cancer. However, the difference between Rec-PC and primary metastatic pancreatic cancer (PM-PC) did not know well. Thus, whether Rec-PC and PM-PC should be included in the same category when conducting clinical trials evaluating chemotherapy remains controversial. The purpose of this study is to investigate the difference of overall survival (OS) between Rec-PC and PM-PC, and analyze their impact on prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy agents | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- chemotherapy for metastatic pancreatic cancer
- description
- chemotherapy
- interventionNames
- Drug: chemotherapy agents
- label
- chemotherapy for recurrent pancreatic cancer
- description
- postoperative chemotherapy
- interventionNames
- Drug: chemotherapy agents
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From date of evaluation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * unresectable pancreatic cancer Exclusion Criteria: * Patients expected to survive for less than three months
References
Publications (1)
- DERIVEDSakamoto S, Tabuchi M, Tokumaru T, Uemura S, Tamura S, Yoshimatsu R, Matsumoto M, Iwata J, Iiyama T, Okabayashi T. Does Recurrent Pancreatic Cancer Have Similar Outcomes Compared With Primary Metastatic Pancreatic Cancer? J Surg Oncol. 2026 May;133(6):763-772. doi: 10.1002/jso.70222. Epub 2026 Mar 1. PMID 41766110